Patents by Inventor Bernard Barlaam

Bernard Barlaam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHEMICAL COMPOUNDS
    Publication number: 20220340592
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Application
    Filed: April 27, 2022
    Publication date: October 27, 2022
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Pyridine and pyrimidine derivatives
    Patent number: 11352369
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 7, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • CHEMICAL COMPOUNDS
    Publication number: 20210171541
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Application
    Filed: July 17, 2020
    Publication date: June 10, 2021
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Chemical compounds
    Patent number: 10717746
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 21, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • CHEMICAL COMPOUNDS
    Publication number: 20180093998
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Application
    Filed: December 6, 2017
    Publication date: April 5, 2018
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Chemical compounds
    Patent number: 9845331
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: December 19, 2017
    Assignee: AstraZeneca AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Chemical Compounds
    Publication number: 20160376287
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Application
    Filed: June 27, 2016
    Publication date: December 29, 2016
    Applicant: AstraZeneca AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
    Patent number: 8318752
    Abstract: The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: November 27, 2012
    Assignee: Astrazeneca AB
    Inventor: Bernard Barlaam
  • NOVEL COMPOUNDS
    Publication number: 20120095011
    Abstract: The invention provides compounds of formula in which R1, R2, R3 and R4 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
    Type: Application
    Filed: December 7, 2011
    Publication date: April 19, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Andrew Pape, Andrew Thomas
  • NOVEL COMPOUNDS
    Publication number: 20090131463
    Abstract: The invention provides compounds of formula in which R1, R2, R3 and R4 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
    Type: Application
    Filed: January 26, 2009
    Publication date: May 21, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Andrew Pape, Andrew Thomas
  • Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-I)
    Patent number: 7521453
    Abstract: The invention provides compounds of formula in which R1, R2, R3 and R4 have the meanings defined in the specification; processes for the preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: April 21, 2009
    Assignee: AstraZeneca AB
    Inventors: Bernard Barlaam, Andrew Pape, Andrew Thomas
  • Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
    Publication number: 20070232607
    Abstract: The invention concerns quinazoline derivatives of the formula (I), wherein each of R1, R2, R3, R4, R5, R6, R7, X1, Q1, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Application
    Filed: June 2, 2005
    Publication date: October 4, 2007
    Inventors: Robert Bradbury, Jason Kettle, James Scott, Bernard Barlaam
  • ER-beta-selective ligands
    Publication number: 20070208066
    Abstract: Compounds of the formula (I) for use as an estrogen receptor -?-selective ligand are described wherein: X is O or S; and R1, R3-R6 are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.
    Type: Application
    Filed: October 11, 2005
    Publication date: September 6, 2007
    Inventors: Bernard Barlaam, Peter Bernstein, Cathy Dantzman, Paul Warwick
  • Selective estrogen receptor-? ligands
    Patent number: 7256201
    Abstract: The invention relates to novel compounds having the general formula: (I) and arc useful as selective ER-? ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis cardiovascular disease, rheumatoid arthritis or prostate cancer.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: August 14, 2007
    Assignee: AstraZeneca AB
    Inventors: Bernard Barlaam, Cathy Dantzman
  • Estrogen receptor-? ligands
    Patent number: 7226945
    Abstract: A method for treating a disease associated with the estrogen receptor-?, comprising the step of administiering a therapeutically-effective amount of a compound that satifies the equation: Ki?A/Ki?A>25, optionally having general structure (I).
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: June 5, 2007
    Assignee: AstraZeneca AB
    Inventors: Bernard Barlaam, James J. Folmer, Timothy M. Piser
  • Quinazoline derivatives
    Publication number: 20070037837
    Abstract: The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, R2, X1, R5 and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
    Type: Application
    Filed: September 15, 2004
    Publication date: February 15, 2007
    Inventors: Laurent Francois Hennequin, Bernard Barlaam, Robert Bradbury
  • Quinazoline derivatives as tyrosine kinase inhibitors
    Publication number: 20070032508
    Abstract: A quinazoline derivative of the formula (I); wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
    Type: Application
    Filed: September 14, 2004
    Publication date: February 8, 2007
    Inventors: Robert Bradbury, Jason Kettle, Laurent Hennequin, Bernard Barlaam
  • Therapeutic benimidazole compounds
    Publication number: 20070004713
    Abstract: The invention relates to novel compounds having general formula (I) are useful as selective ER-? ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis or prostate cancer.
    Type: Application
    Filed: December 7, 2001
    Publication date: January 4, 2007
    Inventors: Bernard Barlaam, Steven Dock
  • Quinazoline derivatives as antiproliferative agents
    Publication number: 20060287295
    Abstract: The invention concerns quinazoline derivatives of Formula (I), wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Application
    Filed: September 22, 2004
    Publication date: December 21, 2006
    Inventors: Bernard Barlaam, Laurent Hennequin, Christopher Halsall
  • Therapeutic benzothiazole compounds
    Publication number: 20060111408
    Abstract: Compounds of the formula (I) for use as an estrogen receptor -?-selective ligand are described wherein: X is O or S; and R1, R3-R6 are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.
    Type: Application
    Filed: January 3, 2006
    Publication date: May 25, 2006
    Inventors: Bernard Barlaam, Peter Bernstein, Cathy Dantzman, Paul Warwick